Optison (Perflutren)

Perflutren forms microbubbles with a gas core and a lipid shell. After injection, these microbubbles remain intravascular and reflect ultrasound waves much more strongly than surrounding tissue, increasing backscatter and producing enhanced image contrast during echocardiographic examinations.

The dose of Optison is determined by the prescribing clinician based on the specific imaging protocol, patient weight, and equipment settings. The product is supplied as a ready‑to‑use suspension, and the prescriber sets the exact volume to be administered.

Limited clinical data are available for Optison in pregnant or lactating women. Because the agent crosses the placental barrier and its safety profile is not fully established, it should only be used when clearly needed and after a careful risk‑benefit assessment by the treating physician.

To order Optison, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Optison (perflutren) is comparable to other lipid‑based agents such as Definity, offering similar microbubble size and imaging enhancement. Differences may include formulation stability, required storage conditions, and specific licensing in various regions. Clinicians choose based on institutional protocols, availability, and regulatory status.

Optison must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. The suspension should be kept in its original container until use, and any unused portion should be discarded according to local regulations.

Optison is administered as an intravenous injection, typically as a bolus followed by a saline flush. The injection is performed under the supervision of a qualified healthcare professional while the ultrasound machine is set to a low mechanical‑index mode to maximize contrast effect.

The most serious risks include severe allergic reactions such as anaphylaxis, cardiopulmonary arrest, persistent hypotension, and acute pulmonary hypertension. Immediate medical intervention is required if any of these events occur during or after administration.

Optison should not be used in patients with known hypersensitivity to perflutren or any formulation component, in those with right‑to‑left cardiac shunts, severe pulmonary hypertension, or in individuals who have experienced a severe reaction to another ultrasound contrast agent.